Protalix BioTherapeutics (PLX) Misses Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.27 --0%
EPS Growth %: +400.0%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES: -6.35M
Today's EPS Names:
XOM, GIGM, VEON, More
EPS Growth %: +400.0%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES: -6.35M
Today's EPS Names:
XOM, GIGM, VEON, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q3 EPS of $0.03, $0.04 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $17.67 million versus the consensus estimate of $17.79 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regal-Beloit (RBC) Tops Q1 EPS by 47c; offers guidance
- Moderna (MRNA) Tops Q2 EPS by 6c, Beats on Revenue
- Balchem Corp. (BCPC) Tops Q2 EPS by 24c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
